Vicore Pharma Holding AB (publ) (VICO.ST)

SEK 6.38

(-0.31%)

Market Cap (In SEK)

1.49 Billion

Revenue (In SEK)

-

Net Income (In SEK)

-310.94 Million

Avg. Volume

365.74 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.92-24.1
PE
-5.19
EPS
-1.23
Beta Value
0.633
ISIN
SE0007577895
CUSIP
-
CIK
-
Shares
234579000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ahmed S. Mousa J.D.
Employee Count
-
Website
https://www.vicorepharma.com
Ipo Date
2015-12-10
Details
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.